🌍·4h agoMedia
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Publisher
N
Novartis
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on novartis.com
Leave the platform to read the original full article on the publisher site.
Source: Novartis
Scope: Media
Related coverage
More related coverage
AACR·3h ago
Stopping Cancer Before It Starts in Lynch Syndrome
ABPI UK·3h ago
Taking control: Inspiring others to beat rare diseases
Erasmus University Rotterdam·3h ago
Paul van Geest presents Erasmus University research to Pope Leo XIV in Rome
ABPI UK·4h ago